Quick Heal Technologies（QUICKHEAL）株式概要クイック・ヒール・テクノロジーズ社は、インド内外の消費者、中小企業、政府機関、企業向けにセキュリティ・ソフトウェア製品とソリューションの提供を行っている。 詳細QUICKHEAL ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析Indian市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去5年間で収益は年間55.2%減少しました。 すべてのリスクチェックを見るQUICKHEAL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹173.62256.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-109m3b2016201920222025202620282031Revenue ₹2.0bEarnings ₹236.1mAdvancedSet Fair ValueView all narrativesQuick Heal Technologies Limited 競合他社ABM KnowledgewareSymbol: BSE:531161Market cap: ₹4.2b3i InfotechSymbol: NSEI:3IINFOLTDMarket cap: ₹3.7bRamco SystemsSymbol: NSEI:RAMCOSYSMarket cap: ₹21.4bTAC InfosecSymbol: NSEI:TACMarket cap: ₹8.2b価格と性能株価の高値、安値、推移の概要Quick Heal Technologies過去の株価現在の株価₹173.6252週高値₹416.7052週安値₹125.00ベータ0.131ヶ月の変化-14.23%3ヶ月変化20.54%1年変化-51.15%3年間の変化7.11%5年間の変化-35.48%IPOからの変化-31.61%最新ニュースReported Earnings • May 23Full year 2026 earnings released: ₹1.98 loss per share (vs ₹0.94 profit in FY 2025)Full year 2026 results: ₹1.98 loss per share (down from ₹0.94 profit in FY 2025). Revenue: ₹2.84b (up 1.5% from FY 2025). Net loss: ₹109.3m (down 317% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026分析記事 • Jan 21Quick Heal Technologies Limited (NSE:QUICKHEAL) May Have Run Too Fast Too Soon With Recent 26% Price PlummetUnfortunately for some shareholders, the Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has dived 26% in...最新情報をもっと見るRecent updatesReported Earnings • May 23Full year 2026 earnings released: ₹1.98 loss per share (vs ₹0.94 profit in FY 2025)Full year 2026 results: ₹1.98 loss per share (down from ₹0.94 profit in FY 2025). Revenue: ₹2.84b (up 1.5% from FY 2025). Net loss: ₹109.3m (down 317% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026分析記事 • Jan 21Quick Heal Technologies Limited (NSE:QUICKHEAL) May Have Run Too Fast Too Soon With Recent 26% Price PlummetUnfortunately for some shareholders, the Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has dived 26% in...Reported Earnings • Oct 19Second quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.77 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.43 (up from ₹0.77 in 2Q 2025). Revenue: ₹879.0m (up 20% from 2Q 2025). Net income: ₹79.1m (up 91% from 2Q 2025). Profit margin: 9.0% (up from 5.6% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.お知らせ • Sep 02+ 2 more updatesQuick Heal Technologies Limited to Report Q3, 2026 Results on Feb 14, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results on Feb 14, 2026お知らせ • Sep 01Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.Reported Earnings • Aug 08First quarter 2026 earnings released: ₹1.00 loss per share (vs ₹0.75 profit in 1Q 2025)First quarter 2026 results: ₹1.00 loss per share (down from ₹0.75 profit in 1Q 2025). Revenue: ₹629.8m (down 10% from 1Q 2025). Net loss: ₹55.1m (down 237% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.お知らせ • Aug 02Quick Heal Technologies Limited to Report Q1, 2026 Results on Aug 07, 2025Quick Heal Technologies Limited announced that they will report Q1, 2026 results on Aug 07, 2025New Risk • Jul 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (1.8% net profit margin).分析記事 • Jul 03Optimistic Investors Push Quick Heal Technologies Limited (NSE:QUICKHEAL) Shares Up 30% But Growth Is LackingThe Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has done very well over the last month, posting an...New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin).分析記事 • May 18Quick Heal Technologies Limited's (NSE:QUICKHEAL) Business Is Yet to Catch Up With Its Share PriceYou may think that with a price-to-sales (or "P/S") ratio of 5.8x Quick Heal Technologies Limited ( NSE:QUICKHEAL ) is...Reported Earnings • May 10Full year 2025 earnings released: EPS: ₹0.94 (vs ₹4.56 in FY 2024)Full year 2025 results: EPS: ₹0.94 (down from ₹4.56 in FY 2024). Revenue: ₹3.00b (up 2.9% from FY 2024). Net income: ₹50.4m (down 79% from FY 2024). Profit margin: 1.7% (down from 8.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.お知らせ • May 01Quick Heal Technologies Limited to Report Q4, 2025 Results on May 06, 2025Quick Heal Technologies Limited announced that they will report Q4, 2025 results on May 06, 2025分析記事 • Apr 10These Return Metrics Don't Make Quick Heal Technologies (NSE:QUICKHEAL) Look Too StrongIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...お知らせ • Apr 01Quick Heal Technologies Limited Announces Resignation of Shailesh Lakhani as DirectorQuick Heal Technologies Limited announced resignation of Mr. Shailesh Lakhani as Director with effect from 31 March 2025.Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹296, the stock trades at a trailing P/E ratio of 71.5x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 73% over the past three years.Reported Earnings • Feb 05Third quarter 2025 earnings released: EPS: ₹0.02 (vs ₹1.89 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.02 (down from ₹1.89 in 3Q 2024). Revenue: ₹755.2m (down 7.8% from 3Q 2024). Net income: ₹1.10m (down 99% from 3Q 2024). Profit margin: 0.1% (down from 12% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.お知らせ • Jan 29Quick Heal Technologies Limited to Report Q3, 2025 Results on Feb 04, 2025Quick Heal Technologies Limited announced that they will report Q3, 2025 results at 12:08 PM, Indian Standard Time on Feb 04, 2025分析記事 • Jan 28Quick Heal Technologies Limited's (NSE:QUICKHEAL) 29% Share Price Plunge Could Signal Some RiskQuick Heal Technologies Limited ( NSE:QUICKHEAL ) shareholders won't be pleased to see that the share price has had a...Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹468, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 37x in the Software industry in India. Total returns to shareholders of 134% over the past three years.お知らせ • Dec 04Quick Heal Technologies Limited Launches Seqrite Malware Analysis Platform and Threat Intel SolutionQuick Heal Technologies Limited announced that the company announce the launch of its new product on 4 December, 2024 and issue of India Cyber Threat Report 2025. The product named Seqrite Malware Analysis Platform (SMAP) and Threat Intel Solution is set to launch on 4 December 2024. It falls under the category of Enterprise Security Software, specifically designed as a Malware Analysis Platform and Threat Intel Solution. This product will cater to the domestic market initially, with the first phase being introduced in the Domestic Market and plans to subsequently expand into other geographies.New Risk • Nov 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹19m sold).分析記事 • Nov 13Quick Heal Technologies Limited (NSE:QUICKHEAL) May Have Run Too Fast Too Soon With Recent 26% Price PlummetThe Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has softened a substantial 26% over the previous 30...分析記事 • Oct 25Impressive Earnings May Not Tell The Whole Story For Quick Heal Technologies (NSE:QUICKHEAL)Despite announcing strong earnings, Quick Heal Technologies Limited's ( NSE:QUICKHEAL ) stock was sluggish. We think...Reported Earnings • Oct 18Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹2.43 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.77 (down from ₹2.43 in 2Q 2024). Revenue: ₹786.9m (flat on 2Q 2024). Net income: ₹41.5m (down 68% from 2Q 2024). Profit margin: 5.3% (down from 17% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.お知らせ • Oct 11Quick Heal Technologies Limited to Report Q2, 2025 Results on Oct 17, 2024Quick Heal Technologies Limited announced that they will report Q2, 2025 results on Oct 17, 2024お知らせ • Oct 04Quick Heal Technologies Limited Announces the Launch of India's First Fraud Prevention Solution - AntiFraud.AIQuick Heal Technologies Limited announced the launch of India's first fraud prevention solution - AntiFraud.AI. This 'Made in India' solution opens a whole new category revolutionizing digital safety against the escalating threat of financial frauds which is impacting everyone including the most tech-savvy. The launch of AntiFraud.AI comes at a crucial time when financial fraud has reached alarming levels. According to the Indian Cybercrime Coordination Centre, the approximate amount that Indians lost to fraudsters between January to April 2024 stood at 1750 crores. The gravity of the situation is further underlined by the National Cybercrime Reporting Portal, suffered losses were reported through over 740,000 complaints. These staggering figures highlight the urgent need for comprehensive fraud prevention solutions, a need that Quick Heal's AntiFraud.AI aims to address head-on. AntiFraud.AI boasts a wide range of robust features designed to enhance user security and safeguard sensitive information. Key Features Include: 1. Risk Profile - Assess risk level with actionable recommendations to reduce exposure to fraud. 2. Fraud Call Alert - Alerts on receiving a potentially fraudulent call. 3. Scam Protection - Employs sophisticated algorithms to identify and block phishing links and fraudulent websites, enhancing online security. 4. Banking Fraud Alert - Utilizes artificial intelligence to detect and alert users to potential banking fraud attempts in real-time. 5. Fraud Protect Buddy - Empowers users to safeguard their loved ones by sharing alerts and security tips, specifically addressing the vulnerabilities of less tech-savvy individuals. 6. Fraud App Detector - Continuously scans for malicious applications and delivers real-time alerts about potentially harmful apps. 7. Secure Payments - Ensures a safe environment for online transactions and monitors for suspicious activity throughout the payment process. Unauthorized Access Alert - Notifies users if their device's microphone or camera is activated without consent, protecting against covert surveillance. Dark Web Monitoring - Actively scans the dark web for compromised sensitive data and provides timely notifications if users' information is found. . Call Forwarding Alert - Alerts when calls are being redirected without consent, The solution also offers Screen share alert, Payee Name Announcer, Spy Alert, File Vault and Browsing Protection and more. In addition to these, The Information Hub feature provides access to in-depth research and fraud intelligence from Seqrite Labs, India's largest malware analysis facility, keeping users informed about evolving threats with the latest fraud trends and prevention tips. This feature allows users to access Quick Heal's extensive domain expertise and knowledge. Furthermore, the Victim Support feature offers step- by-step guidance for those who fall victim to fraud, aiding in recovery and necessary actions. Together, these elements create a robust defense against fraud and enhance overall digital security.Board Change • Oct 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Kamal Agarwal was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 09Quick Heal Technologies Limited Appoints Kamal Kumar Agarwal as an Independent DirectorQuick Heal Technologies Limited approved the appointment of Mr. Kamal Kumar Agarwal as an Independent Director of the company for a first term of five years commencing from July 26, 2024 at the AGM held on September 06, 2024. Mr. Kamal Kumar Agarwal 43, is a graduate in Bachelor of Commerce in year 2001. He is a Member of the Institute of Chartered Accountants of India. Part of CFO 100 2013 and 2016 Honor list under 'Winning Edge in a Finance Start-up. Mr. Kamal Kumar Agarwal, serving /served as Non-Executive Director & Investor Advisor for M/s NewCold, MN Bio-Technology, Giant Connection & a few. Mr. Kamal Kumar Agarwal has served as Group CFO - Indian Subcontinent & Director at Ferrero India Private Limited. He was also worked with blue chip companies Cadbury India Private Limited, ITC Limited and Tata Teleservices Limited. Currently incubating two additional ventures since Fiscal Year 22/23 Hampa Wellness (a hemp-based product co.) and Peaceful Progress LLP (Cat 1 SEBI approved AIF 20 investments till date). In the past, have built and sold - Winter Logistics to M/s Dubai Port. Management Buy Out (by-self), and Multi Million Dollars PE-funding (Goldman Sachs and Mitsui) of The Good Stuff Private Limited a venture focused on FMCG that has seen Sell Out to M/s DS Group. Mr. Kamal Kumar Agarwal is not related to any director of the company.分析記事 • Sep 05Revenues Not Telling The Story For Quick Heal Technologies Limited (NSE:QUICKHEAL) After Shares Rise 27%Quick Heal Technologies Limited ( NSE:QUICKHEAL ) shares have continued their recent momentum with a 27% gain in the...Upcoming Dividend • Aug 23Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 30 August 2024. Payment date: 06 October 2024. Payout ratio is a comfortable 66% but the company is paying out more than the cash it is generating. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (1.2%).お知らせ • Aug 16Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024, at 16:00 Indian Standard Time.Reported Earnings • Jul 27First quarter 2025 earnings released: EPS: ₹0.75 (vs ₹2.40 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.75 (up from ₹2.40 loss in 1Q 2024). Revenue: ₹753.5m (up 47% from 1Q 2024). Net income: ₹40.3m (up ₹167.9m from 1Q 2024). Profit margin: 5.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.分析記事 • Jul 23Quick Heal Technologies' (NSE:QUICKHEAL) Returns On Capital Tell Us There Is Reason To Feel UneasyWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...お知らせ • Jul 18Quick Heal Technologies Limited to Report Q1, 2025 Results on Jul 26, 2024Quick Heal Technologies Limited announced that they will report Q1, 2025 results on Jul 26, 2024分析記事 • Jul 05Revenues Not Telling The Story For Quick Heal Technologies Limited (NSE:QUICKHEAL) After Shares Rise 26%Quick Heal Technologies Limited ( NSE:QUICKHEAL ) shareholders would be excited to see that the share price has had a...Reported Earnings • Apr 26Full year 2024 earnings released: EPS: ₹4.56 (vs ₹1.14 in FY 2023)Full year 2024 results: EPS: ₹4.56 (up from ₹1.14 in FY 2023). Revenue: ₹3.13b (up 13% from FY 2023). Net income: ₹242.4m (up 279% from FY 2023). Profit margin: 7.7% (up from 2.3% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.お知らせ • Apr 26Quick Heal Technologies Limited Recommends Final Dividend for the Year 2023-24Quick Heal Technologies Limited has recommended a final dividend of 3 per equity share of 10/- each for the year 2023-24 subject to approval of shareholders in ensuing AGM.お知らせ • Apr 19Quick Heal Technologies Limited to Report Q4, 2024 Results on Apr 25, 2024Quick Heal Technologies Limited announced that they will report Q4, 2024 results at 4:00 PM, Indian Standard Time on Apr 25, 2024Recent Insider Transactions • Mar 12Head of Retail Sales recently sold ₹1.1m worth of stockOn the 4th of March, Deepak Mishra sold around 2k shares on-market at roughly ₹565 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹41m more than they bought in the last 12 months.Recent Insider Transactions • Mar 06Head of Retail Sales recently sold ₹3.5m worth of stockOn the 1st of March, Deepak Mishra sold around 6k shares on-market at roughly ₹545 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹40m more than they bought in the last 12 months.お知らせ • Jan 25Quick Heal Technologies Limited Announces Appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product OfficerQuick Heal Technologies Limited announced the appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product Officer, effective from January 24, 2024. Dr. Lalit is PHD in Computer Science and Bachelor of Engineering from IIT Hyderabad in Threat Intelligence. He has experience of over 25 year in IT and Cyber Security Industry.Reported Earnings • Jan 25Third quarter 2024 earnings released: EPS: ₹1.89 (vs ₹1.70 loss in 3Q 2023)Third quarter 2024 results: EPS: ₹1.89 (up from ₹1.70 loss in 3Q 2023). Revenue: ₹860.7m (up 29% from 3Q 2023). Net income: ₹100.6m (up ₹193.5m from 3Q 2023). Profit margin: 12% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.分析記事 • Jan 17Quick Heal Technologies Limited's (NSE:QUICKHEAL) Share Price Not Quite Adding UpWith a price-to-sales (or "P/S") ratio of 9.1x Quick Heal Technologies Limited ( NSE:QUICKHEAL ) may be sending very...お知らせ • Jan 11Quick Heal Technologies Limited to Report Q2, 2024 Results on Jan 24, 2024Quick Heal Technologies Limited announced that they will report Q2, 2024 results on Jan 24, 2024Recent Insider Transactions • Dec 20Chief Product Officer recently sold ₹29m worth of stockOn the 15th of December, Sanjay Agrawal sold around 77k shares on-market at roughly ₹369 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Oct 29Second quarter 2024 earnings released: EPS: ₹2.43 (vs ₹3.82 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.43 (down from ₹3.82 in 2Q 2023). Revenue: ₹840.5m (down 17% from 2Q 2023). Net income: ₹129.0m (down 42% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.お知らせ • Oct 28Quick Heal Technologies Limited Appoints Sarang Deshpande as Company Secretary and Compliance OfficerQuick Heal Technologies Limited announced the appointment of Mr. Sarang Deshpande as company Secretary and Compliance Officer. Date of appointment is 26 October, 2023. Mr. Sarang Deshpande is a member of Institute of Company Secretaries of India (ICSI). He is a Bachelor of Legislative Law (LL.B.) and Master of Commerce (M.Com) having more than 18 years of experience in the field of secretarial, legal and compliance of listed and unlisted companies.お知らせ • Sep 13Quick Heal Technologies Limited Announces the Resignation of Vinav Agarwal as Compliance Officer, Effective September 15, 2023Quick Heal Technologies Limited announced the resignation of Mr. Vinav Agarwal as Compliance Officer, due to personal reasons. Date of cessation is September 15, 2023.Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Richard Stiennon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Share price has been volatile over the past 3 months (7.4% average weekly change).分析記事 • Jul 23Quick Heal Technologies (NSE:QUICKHEAL) Is Paying Out Less In Dividends Than Last YearQuick Heal Technologies Limited ( NSE:QUICKHEAL ) is reducing its dividend from last year's comparable payment to ₹2.50...お知らせ • Jul 22Quick Heal Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023Quick Heal Technologies Limited at its Annual General Meeting to be held on August 11, 2023, proposed to declare a final dividend of INR 2.50 per equity share of face value INR 10 each for the financial year ended March 31, 2023.New Risk • Jul 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.08b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Market cap is less than US$100m (₹8.08b market cap, or US$98.5m).Reported Earnings • Jul 21First quarter 2024 earnings released: ₹2.40 loss per share (vs ₹0.03 profit in 1Q 2023)First quarter 2024 results: ₹2.40 loss per share (down from ₹0.03 profit in 1Q 2023). Revenue: ₹561.7m (down 8.0% from 1Q 2023). Net loss: ₹127.6m (down ₹129.4m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Jul 18Quick Heal Technologies Limited Announces Resignation of Srinivasa Rao as Company Secretary & Key Managerial PersonQuick Heal Technologies Limited announced that Mr. A. Srinivasa Rao, has given the resignation from the post of Company Secretary & Key Managerial Person (KMP) of Company vide his resignation letter as received on July 17, 2023 due to personal reasons.お知らせ • Jul 15Quick Heal Technologies Limited to Report Q1, 2024 Results on Jul 20, 2023Quick Heal Technologies Limited announced that they will report Q1, 2024 results on Jul 20, 2023お知らせ • Jul 04+ 1 more updateQuick Heal Technologies Limited Announces Management ChangesQuick Heal Technologies Limited at its board meeting held on July 03, 2023 re- designated Mr. Kailash Katkar as Managing Director with effect from July 03, 2023 and re-designated Mr. Sanjay Katkar, Joint Managing Director & CTO as Joint Managing Director with effect from July 03, 2023.Reported Earnings • Apr 19Full year 2023 earnings released: EPS: ₹1.14 (vs ₹14.01 in FY 2022)Full year 2023 results: EPS: ₹1.14 (down from ₹14.01 in FY 2022). Revenue: ₹3.00b (down 12% from FY 2022). Net income: ₹64.0m (down 92% from FY 2022). Profit margin: 2.1% (down from 24% in FY 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.分析記事 • Apr 06Quick Heal Technologies' (NSE:QUICKHEAL) Returns On Capital Not Reflecting Well On The BusinessWhat financial metrics can indicate to us that a company is maturing or even in decline? A business that's potentially...Reported Earnings • Jan 25Third quarter 2023 earnings released: ₹1.70 loss per share (vs ₹2.47 profit in 3Q 2022)Third quarter 2023 results: ₹1.70 loss per share (down from ₹2.47 profit in 3Q 2022). Revenue: ₹702.7m (down 12% from 3Q 2022). Net loss: ₹92.9m (down 165% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year.お知らせ • Jan 17Quick Heal Technologies Limited to Report Q3, 2023 Results on Jan 24, 2023Quick Heal Technologies Limited announced that they will report Q3, 2023 results on Jan 24, 2023Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹3.82 (vs ₹5.39 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.82 (down from ₹5.39 in 2Q 2022). Revenue: ₹1.01b (down 2.7% from 2Q 2022). Net income: ₹221.6m (down 36% from 2Q 2022). Profit margin: 22% (down from 33% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Buying Opportunity • Sep 21Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₹242, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 3.3%.Recent Insider Transactions • Sep 15Insider recently sold ₹4.4m worth of stockOn the 9th of September, Reetu Raina sold around 20k shares on-market at roughly ₹221 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.Upcoming Dividend • Aug 11Upcoming dividend of ₹4.50 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 26 September 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.6%).Reported Earnings • Jul 22First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.97 in 1Q 2022)First quarter 2023 results: EPS: ₹0.03 (down from ₹0.97 in 1Q 2022). Revenue: ₹642.8m (up 17% from 1Q 2022). Net income: ₹1.80m (down 97% from 1Q 2022). Profit margin: 0.3% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹200, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 64% over the past three years.Recent Insider Transactions • Jun 01Head of Research & Development recently sold ₹2.9m worth of stockOn the 25th of May, Bibhuti Kar sold around 16k shares on-market at roughly ₹179 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹14m more than they bought in the last 12 months.Reported Earnings • May 07Full year 2022 earnings released: EPS: ₹14.01 (vs ₹16.66 in FY 2021)Full year 2022 results: EPS: ₹14.01 (down from ₹16.66 in FY 2021). Revenue: ₹3.61b (up 8.4% from FY 2021). Net income: ₹831.9m (down 22% from FY 2021). Profit margin: 23% (down from 32% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 16Head of Research & Development recently sold ₹1.0m worth of stockOn the 14th of February, Bibhuti Kar sold around 5k shares on-market at roughly ₹203 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.7m. Insiders have been net sellers, collectively disposing of ₹12m more than they bought in the last 12 months.分析記事 • Jan 26We Like These Underlying Return On Capital Trends At Quick Heal Technologies (NSE:QUICKHEAL)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Reported Earnings • Jan 25Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹2.47 (up from ₹2.10 in 3Q 2021). Revenue: ₹832.5m (up 19% from 3Q 2021). Net income: ₹142.9m (up 6.1% from 3Q 2021). Profit margin: 17% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.Recent Insider Transactions • Dec 04Insider recently sold ₹9.7m worth of stockOn the 2nd of December, Nitin Kulkarni sold around 45k shares on-market at roughly ₹217 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Aug 14Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹234, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Software industry in India. Total loss to shareholders of 6.2% over the past three years.分析記事 • Jul 30Most Shareholders Will Probably Agree With Quick Heal Technologies Limited's (NSE:QUICKHEAL) CEO CompensationCEO Kailash Katkar has done a decent job of delivering relatively good performance at Quick Heal Technologies Limited...Upcoming Dividend • Jul 22Upcoming dividend of ₹4.00 per shareEligible shareholders must have bought the stock before 29 July 2021. Payment date: 05 September 2021. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.8%).Reported Earnings • Jul 15Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.33b (up 16% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 32% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.Recent Insider Transactions • Jun 03Insider recently sold ₹1.6m worth of stockOn the 31st of May, Manish Jain sold around 8k shares on-market at roughly ₹216 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹2.9m more than they bought in the last 12 months.分析記事 • May 31Investors Will Want Quick Heal Technologies' (NSE:QUICKHEAL) Growth In ROCE To PersistWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...Valuation Update With 7 Day Price Move • May 22Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹227, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 18x in the Software industry in India. Total loss to shareholders of 21% over the past three years.Reported Earnings • May 16Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.57b (up 25% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹181, the stock is trading at a trailing P/E ratio of 14.7x, up from the previous P/E ratio of 12.4x. This compares to an average P/E of 18x in the Software industry in India. Total return to shareholders over the past three years is a loss of 27%.Is New 90 Day High Low • Mar 05New 90-day high: ₹181The company is up 12% from its price of ₹161 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 27% over the same period.分析記事 • Feb 17Does Quick Heal Technologies' (NSE:QUICKHEAL) CEO Salary Compare Well With The Performance Of The Company?The CEO of Quick Heal Technologies Limited ( NSE:QUICKHEAL ) is Kailash Katkar, and this article examines the...Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹2.10 (vs ₹2.77 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹698.8m (up 6.3% from 3Q 2020). Net income: ₹134.6m (down 24% from 3Q 2020). Profit margin: 19% (down from 27% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.分析記事 • Feb 04Are Quick Heal Technologies Limited's (NSE:QUICKHEAL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?Quick Heal Technologies (NSE:QUICKHEAL) has had a rough month with its share price down 8.1%. But if you pay close...分析記事 • Jan 17Should We Be Excited About The Trends Of Returns At Quick Heal Technologies (NSE:QUICKHEAL)?If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...分析記事 • Dec 28If You Had Bought Quick Heal Technologies' (NSE:QUICKHEAL) Shares Three Years Ago You Would Be Down 49%In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...分析記事 • Dec 10What Type Of Shareholders Make Up Quick Heal Technologies Limited's (NSE:QUICKHEAL) Share Registry?The big shareholder groups in Quick Heal Technologies Limited ( NSE:QUICKHEAL ) have power over the company...分析記事 • Nov 22Need To Know: Quick Heal Technologies Limited (NSE:QUICKHEAL) Insiders Have Been Selling SharesWe've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...Reported Earnings • Nov 07Second quarter 2021 earnings released: EPS ₹4.49The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹902.4m (down 8.5% from 2Q 2020). Net income: ₹288.4m (down 22% from 2Q 2020). Profit margin: 32% (down from 37% in 2Q 2020). The decrease in margin was driven by lower revenue.株主還元QUICKHEALIN SoftwareIN 市場7D0.3%1.0%2.2%1Y-51.1%-18.9%-0.5%株主還元を見る業界別リターン: QUICKHEAL過去 1 年間で-18.9 % の収益を上げたIndian Software業界を下回りました。リターン対市場: QUICKHEALは、過去 1 年間で-0.5 % のリターンを上げたIndian市場を下回りました。価格変動Is QUICKHEAL's price volatile compared to industry and market?QUICKHEAL volatilityQUICKHEAL Average Weekly Movement10.6%Software Industry Average Movement7.8%Market Average Movement7.1%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.7%安定した株価: QUICKHEALの株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: QUICKHEALの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1995973Kailash Katkarwww.quickheal.co.inクイック・ヒール・テクノロジーズ社は、インド国内外の消費者、中小企業、政府機関、企業向けにセキュリティ・ソフトウェア製品とソリューションの提供に従事している。コンシューマー部門、企業・政府部門を通じて事業を展開している。クイック・ヒールのブランドで、トータル・セキュリティ、インターネット・セキュリティ、アンチウイルス・プロ、Mac用セキュリティ、アンドロイド用トータル・セキュリティ、モバイル・セキュリティ、トータル・セキュリティ・マルチデバイス、インターネット・セキュリティ・エッセンシャル、トータル・セキュリティ・フェスティブ・パックなどのウイルス対策ソリューションを提供している。Seqriteブランドでは、エンドポイントプロテクション、エンドポイントプロテクションクラウド、EDR、XDR、MDR、ZTNZ、エンタープライズモビリティ管理、ワークスペース、データプライバシーを提供している。国内販売代理店、一次代理店、ビジネスパートナー、ウェブサイトおよびeコマース向けに製品を販売している。クイック・ヒール・テクノロジーズ・リミテッドは1995年に設立され、インドのプネーに本社を置いている。もっと見るQuick Heal Technologies Limited 基礎のまとめQuick Heal Technologies の収益と売上を時価総額と比較するとどうか。QUICKHEAL 基礎統計学時価総額₹9.45b収益（TTM）-₹109.30m売上高(TTM)₹2.61b3.6xP/Sレシオ-86.2xPER（株価収益率QUICKHEAL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計QUICKHEAL 損益計算書（TTM）収益₹2.61b売上原価₹42.80m売上総利益₹2.57bその他の費用₹2.68b収益-₹109.30m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.01グロス・マージン98.36%純利益率-4.19%有利子負債／自己資本比率0%QUICKHEAL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 12:02終値2026/06/17 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Quick Heal Technologies Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kameswari V. S. ChavaliFirstCall ResearchVaibhav DhasmanaJefferies LLC
Reported Earnings • May 23Full year 2026 earnings released: ₹1.98 loss per share (vs ₹0.94 profit in FY 2025)Full year 2026 results: ₹1.98 loss per share (down from ₹0.94 profit in FY 2025). Revenue: ₹2.84b (up 1.5% from FY 2025). Net loss: ₹109.3m (down 317% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).
New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).
Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026
分析記事 • Jan 21Quick Heal Technologies Limited (NSE:QUICKHEAL) May Have Run Too Fast Too Soon With Recent 26% Price PlummetUnfortunately for some shareholders, the Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has dived 26% in...
Reported Earnings • May 23Full year 2026 earnings released: ₹1.98 loss per share (vs ₹0.94 profit in FY 2025)Full year 2026 results: ₹1.98 loss per share (down from ₹0.94 profit in FY 2025). Revenue: ₹2.84b (up 1.5% from FY 2025). Net loss: ₹109.3m (down 317% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).
New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).
Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026
分析記事 • Jan 21Quick Heal Technologies Limited (NSE:QUICKHEAL) May Have Run Too Fast Too Soon With Recent 26% Price PlummetUnfortunately for some shareholders, the Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has dived 26% in...
Reported Earnings • Oct 19Second quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.77 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.43 (up from ₹0.77 in 2Q 2025). Revenue: ₹879.0m (up 20% from 2Q 2025). Net income: ₹79.1m (up 91% from 2Q 2025). Profit margin: 9.0% (up from 5.6% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
お知らせ • Sep 02+ 2 more updatesQuick Heal Technologies Limited to Report Q3, 2026 Results on Feb 14, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results on Feb 14, 2026
お知らせ • Sep 01Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.
Reported Earnings • Aug 08First quarter 2026 earnings released: ₹1.00 loss per share (vs ₹0.75 profit in 1Q 2025)First quarter 2026 results: ₹1.00 loss per share (down from ₹0.75 profit in 1Q 2025). Revenue: ₹629.8m (down 10% from 1Q 2025). Net loss: ₹55.1m (down 237% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
お知らせ • Aug 02Quick Heal Technologies Limited to Report Q1, 2026 Results on Aug 07, 2025Quick Heal Technologies Limited announced that they will report Q1, 2026 results on Aug 07, 2025
New Risk • Jul 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (1.8% net profit margin).
分析記事 • Jul 03Optimistic Investors Push Quick Heal Technologies Limited (NSE:QUICKHEAL) Shares Up 30% But Growth Is LackingThe Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has done very well over the last month, posting an...
New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin).
分析記事 • May 18Quick Heal Technologies Limited's (NSE:QUICKHEAL) Business Is Yet to Catch Up With Its Share PriceYou may think that with a price-to-sales (or "P/S") ratio of 5.8x Quick Heal Technologies Limited ( NSE:QUICKHEAL ) is...
Reported Earnings • May 10Full year 2025 earnings released: EPS: ₹0.94 (vs ₹4.56 in FY 2024)Full year 2025 results: EPS: ₹0.94 (down from ₹4.56 in FY 2024). Revenue: ₹3.00b (up 2.9% from FY 2024). Net income: ₹50.4m (down 79% from FY 2024). Profit margin: 1.7% (down from 8.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
お知らせ • May 01Quick Heal Technologies Limited to Report Q4, 2025 Results on May 06, 2025Quick Heal Technologies Limited announced that they will report Q4, 2025 results on May 06, 2025
分析記事 • Apr 10These Return Metrics Don't Make Quick Heal Technologies (NSE:QUICKHEAL) Look Too StrongIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...
お知らせ • Apr 01Quick Heal Technologies Limited Announces Resignation of Shailesh Lakhani as DirectorQuick Heal Technologies Limited announced resignation of Mr. Shailesh Lakhani as Director with effect from 31 March 2025.
Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹296, the stock trades at a trailing P/E ratio of 71.5x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 73% over the past three years.
Reported Earnings • Feb 05Third quarter 2025 earnings released: EPS: ₹0.02 (vs ₹1.89 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.02 (down from ₹1.89 in 3Q 2024). Revenue: ₹755.2m (down 7.8% from 3Q 2024). Net income: ₹1.10m (down 99% from 3Q 2024). Profit margin: 0.1% (down from 12% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
お知らせ • Jan 29Quick Heal Technologies Limited to Report Q3, 2025 Results on Feb 04, 2025Quick Heal Technologies Limited announced that they will report Q3, 2025 results at 12:08 PM, Indian Standard Time on Feb 04, 2025
分析記事 • Jan 28Quick Heal Technologies Limited's (NSE:QUICKHEAL) 29% Share Price Plunge Could Signal Some RiskQuick Heal Technologies Limited ( NSE:QUICKHEAL ) shareholders won't be pleased to see that the share price has had a...
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹468, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 37x in the Software industry in India. Total returns to shareholders of 134% over the past three years.
お知らせ • Dec 04Quick Heal Technologies Limited Launches Seqrite Malware Analysis Platform and Threat Intel SolutionQuick Heal Technologies Limited announced that the company announce the launch of its new product on 4 December, 2024 and issue of India Cyber Threat Report 2025. The product named Seqrite Malware Analysis Platform (SMAP) and Threat Intel Solution is set to launch on 4 December 2024. It falls under the category of Enterprise Security Software, specifically designed as a Malware Analysis Platform and Threat Intel Solution. This product will cater to the domestic market initially, with the first phase being introduced in the Domestic Market and plans to subsequently expand into other geographies.
New Risk • Nov 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹19m sold).
分析記事 • Nov 13Quick Heal Technologies Limited (NSE:QUICKHEAL) May Have Run Too Fast Too Soon With Recent 26% Price PlummetThe Quick Heal Technologies Limited ( NSE:QUICKHEAL ) share price has softened a substantial 26% over the previous 30...
分析記事 • Oct 25Impressive Earnings May Not Tell The Whole Story For Quick Heal Technologies (NSE:QUICKHEAL)Despite announcing strong earnings, Quick Heal Technologies Limited's ( NSE:QUICKHEAL ) stock was sluggish. We think...
Reported Earnings • Oct 18Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹2.43 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.77 (down from ₹2.43 in 2Q 2024). Revenue: ₹786.9m (flat on 2Q 2024). Net income: ₹41.5m (down 68% from 2Q 2024). Profit margin: 5.3% (down from 17% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.
お知らせ • Oct 11Quick Heal Technologies Limited to Report Q2, 2025 Results on Oct 17, 2024Quick Heal Technologies Limited announced that they will report Q2, 2025 results on Oct 17, 2024
お知らせ • Oct 04Quick Heal Technologies Limited Announces the Launch of India's First Fraud Prevention Solution - AntiFraud.AIQuick Heal Technologies Limited announced the launch of India's first fraud prevention solution - AntiFraud.AI. This 'Made in India' solution opens a whole new category revolutionizing digital safety against the escalating threat of financial frauds which is impacting everyone including the most tech-savvy. The launch of AntiFraud.AI comes at a crucial time when financial fraud has reached alarming levels. According to the Indian Cybercrime Coordination Centre, the approximate amount that Indians lost to fraudsters between January to April 2024 stood at 1750 crores. The gravity of the situation is further underlined by the National Cybercrime Reporting Portal, suffered losses were reported through over 740,000 complaints. These staggering figures highlight the urgent need for comprehensive fraud prevention solutions, a need that Quick Heal's AntiFraud.AI aims to address head-on. AntiFraud.AI boasts a wide range of robust features designed to enhance user security and safeguard sensitive information. Key Features Include: 1. Risk Profile - Assess risk level with actionable recommendations to reduce exposure to fraud. 2. Fraud Call Alert - Alerts on receiving a potentially fraudulent call. 3. Scam Protection - Employs sophisticated algorithms to identify and block phishing links and fraudulent websites, enhancing online security. 4. Banking Fraud Alert - Utilizes artificial intelligence to detect and alert users to potential banking fraud attempts in real-time. 5. Fraud Protect Buddy - Empowers users to safeguard their loved ones by sharing alerts and security tips, specifically addressing the vulnerabilities of less tech-savvy individuals. 6. Fraud App Detector - Continuously scans for malicious applications and delivers real-time alerts about potentially harmful apps. 7. Secure Payments - Ensures a safe environment for online transactions and monitors for suspicious activity throughout the payment process. Unauthorized Access Alert - Notifies users if their device's microphone or camera is activated without consent, protecting against covert surveillance. Dark Web Monitoring - Actively scans the dark web for compromised sensitive data and provides timely notifications if users' information is found. . Call Forwarding Alert - Alerts when calls are being redirected without consent, The solution also offers Screen share alert, Payee Name Announcer, Spy Alert, File Vault and Browsing Protection and more. In addition to these, The Information Hub feature provides access to in-depth research and fraud intelligence from Seqrite Labs, India's largest malware analysis facility, keeping users informed about evolving threats with the latest fraud trends and prevention tips. This feature allows users to access Quick Heal's extensive domain expertise and knowledge. Furthermore, the Victim Support feature offers step- by-step guidance for those who fall victim to fraud, aiding in recovery and necessary actions. Together, these elements create a robust defense against fraud and enhance overall digital security.
Board Change • Oct 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Kamal Agarwal was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 09Quick Heal Technologies Limited Appoints Kamal Kumar Agarwal as an Independent DirectorQuick Heal Technologies Limited approved the appointment of Mr. Kamal Kumar Agarwal as an Independent Director of the company for a first term of five years commencing from July 26, 2024 at the AGM held on September 06, 2024. Mr. Kamal Kumar Agarwal 43, is a graduate in Bachelor of Commerce in year 2001. He is a Member of the Institute of Chartered Accountants of India. Part of CFO 100 2013 and 2016 Honor list under 'Winning Edge in a Finance Start-up. Mr. Kamal Kumar Agarwal, serving /served as Non-Executive Director & Investor Advisor for M/s NewCold, MN Bio-Technology, Giant Connection & a few. Mr. Kamal Kumar Agarwal has served as Group CFO - Indian Subcontinent & Director at Ferrero India Private Limited. He was also worked with blue chip companies Cadbury India Private Limited, ITC Limited and Tata Teleservices Limited. Currently incubating two additional ventures since Fiscal Year 22/23 Hampa Wellness (a hemp-based product co.) and Peaceful Progress LLP (Cat 1 SEBI approved AIF 20 investments till date). In the past, have built and sold - Winter Logistics to M/s Dubai Port. Management Buy Out (by-self), and Multi Million Dollars PE-funding (Goldman Sachs and Mitsui) of The Good Stuff Private Limited a venture focused on FMCG that has seen Sell Out to M/s DS Group. Mr. Kamal Kumar Agarwal is not related to any director of the company.
分析記事 • Sep 05Revenues Not Telling The Story For Quick Heal Technologies Limited (NSE:QUICKHEAL) After Shares Rise 27%Quick Heal Technologies Limited ( NSE:QUICKHEAL ) shares have continued their recent momentum with a 27% gain in the...
Upcoming Dividend • Aug 23Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 30 August 2024. Payment date: 06 October 2024. Payout ratio is a comfortable 66% but the company is paying out more than the cash it is generating. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (1.2%).
お知らせ • Aug 16Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024, at 16:00 Indian Standard Time.
Reported Earnings • Jul 27First quarter 2025 earnings released: EPS: ₹0.75 (vs ₹2.40 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.75 (up from ₹2.40 loss in 1Q 2024). Revenue: ₹753.5m (up 47% from 1Q 2024). Net income: ₹40.3m (up ₹167.9m from 1Q 2024). Profit margin: 5.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.
分析記事 • Jul 23Quick Heal Technologies' (NSE:QUICKHEAL) Returns On Capital Tell Us There Is Reason To Feel UneasyWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
お知らせ • Jul 18Quick Heal Technologies Limited to Report Q1, 2025 Results on Jul 26, 2024Quick Heal Technologies Limited announced that they will report Q1, 2025 results on Jul 26, 2024
分析記事 • Jul 05Revenues Not Telling The Story For Quick Heal Technologies Limited (NSE:QUICKHEAL) After Shares Rise 26%Quick Heal Technologies Limited ( NSE:QUICKHEAL ) shareholders would be excited to see that the share price has had a...
Reported Earnings • Apr 26Full year 2024 earnings released: EPS: ₹4.56 (vs ₹1.14 in FY 2023)Full year 2024 results: EPS: ₹4.56 (up from ₹1.14 in FY 2023). Revenue: ₹3.13b (up 13% from FY 2023). Net income: ₹242.4m (up 279% from FY 2023). Profit margin: 7.7% (up from 2.3% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 26Quick Heal Technologies Limited Recommends Final Dividend for the Year 2023-24Quick Heal Technologies Limited has recommended a final dividend of 3 per equity share of 10/- each for the year 2023-24 subject to approval of shareholders in ensuing AGM.
お知らせ • Apr 19Quick Heal Technologies Limited to Report Q4, 2024 Results on Apr 25, 2024Quick Heal Technologies Limited announced that they will report Q4, 2024 results at 4:00 PM, Indian Standard Time on Apr 25, 2024
Recent Insider Transactions • Mar 12Head of Retail Sales recently sold ₹1.1m worth of stockOn the 4th of March, Deepak Mishra sold around 2k shares on-market at roughly ₹565 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹41m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 06Head of Retail Sales recently sold ₹3.5m worth of stockOn the 1st of March, Deepak Mishra sold around 6k shares on-market at roughly ₹545 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹40m more than they bought in the last 12 months.
お知らせ • Jan 25Quick Heal Technologies Limited Announces Appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product OfficerQuick Heal Technologies Limited announced the appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product Officer, effective from January 24, 2024. Dr. Lalit is PHD in Computer Science and Bachelor of Engineering from IIT Hyderabad in Threat Intelligence. He has experience of over 25 year in IT and Cyber Security Industry.
Reported Earnings • Jan 25Third quarter 2024 earnings released: EPS: ₹1.89 (vs ₹1.70 loss in 3Q 2023)Third quarter 2024 results: EPS: ₹1.89 (up from ₹1.70 loss in 3Q 2023). Revenue: ₹860.7m (up 29% from 3Q 2023). Net income: ₹100.6m (up ₹193.5m from 3Q 2023). Profit margin: 12% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance.
分析記事 • Jan 17Quick Heal Technologies Limited's (NSE:QUICKHEAL) Share Price Not Quite Adding UpWith a price-to-sales (or "P/S") ratio of 9.1x Quick Heal Technologies Limited ( NSE:QUICKHEAL ) may be sending very...
お知らせ • Jan 11Quick Heal Technologies Limited to Report Q2, 2024 Results on Jan 24, 2024Quick Heal Technologies Limited announced that they will report Q2, 2024 results on Jan 24, 2024
Recent Insider Transactions • Dec 20Chief Product Officer recently sold ₹29m worth of stockOn the 15th of December, Sanjay Agrawal sold around 77k shares on-market at roughly ₹369 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Oct 29Second quarter 2024 earnings released: EPS: ₹2.43 (vs ₹3.82 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.43 (down from ₹3.82 in 2Q 2023). Revenue: ₹840.5m (down 17% from 2Q 2023). Net income: ₹129.0m (down 42% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
お知らせ • Oct 28Quick Heal Technologies Limited Appoints Sarang Deshpande as Company Secretary and Compliance OfficerQuick Heal Technologies Limited announced the appointment of Mr. Sarang Deshpande as company Secretary and Compliance Officer. Date of appointment is 26 October, 2023. Mr. Sarang Deshpande is a member of Institute of Company Secretaries of India (ICSI). He is a Bachelor of Legislative Law (LL.B.) and Master of Commerce (M.Com) having more than 18 years of experience in the field of secretarial, legal and compliance of listed and unlisted companies.
お知らせ • Sep 13Quick Heal Technologies Limited Announces the Resignation of Vinav Agarwal as Compliance Officer, Effective September 15, 2023Quick Heal Technologies Limited announced the resignation of Mr. Vinav Agarwal as Compliance Officer, due to personal reasons. Date of cessation is September 15, 2023.
Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Richard Stiennon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Share price has been volatile over the past 3 months (7.4% average weekly change).
分析記事 • Jul 23Quick Heal Technologies (NSE:QUICKHEAL) Is Paying Out Less In Dividends Than Last YearQuick Heal Technologies Limited ( NSE:QUICKHEAL ) is reducing its dividend from last year's comparable payment to ₹2.50...
お知らせ • Jul 22Quick Heal Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023Quick Heal Technologies Limited at its Annual General Meeting to be held on August 11, 2023, proposed to declare a final dividend of INR 2.50 per equity share of face value INR 10 each for the financial year ended March 31, 2023.
New Risk • Jul 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.08b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Market cap is less than US$100m (₹8.08b market cap, or US$98.5m).
Reported Earnings • Jul 21First quarter 2024 earnings released: ₹2.40 loss per share (vs ₹0.03 profit in 1Q 2023)First quarter 2024 results: ₹2.40 loss per share (down from ₹0.03 profit in 1Q 2023). Revenue: ₹561.7m (down 8.0% from 1Q 2023). Net loss: ₹127.6m (down ₹129.4m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Jul 18Quick Heal Technologies Limited Announces Resignation of Srinivasa Rao as Company Secretary & Key Managerial PersonQuick Heal Technologies Limited announced that Mr. A. Srinivasa Rao, has given the resignation from the post of Company Secretary & Key Managerial Person (KMP) of Company vide his resignation letter as received on July 17, 2023 due to personal reasons.
お知らせ • Jul 15Quick Heal Technologies Limited to Report Q1, 2024 Results on Jul 20, 2023Quick Heal Technologies Limited announced that they will report Q1, 2024 results on Jul 20, 2023
お知らせ • Jul 04+ 1 more updateQuick Heal Technologies Limited Announces Management ChangesQuick Heal Technologies Limited at its board meeting held on July 03, 2023 re- designated Mr. Kailash Katkar as Managing Director with effect from July 03, 2023 and re-designated Mr. Sanjay Katkar, Joint Managing Director & CTO as Joint Managing Director with effect from July 03, 2023.
Reported Earnings • Apr 19Full year 2023 earnings released: EPS: ₹1.14 (vs ₹14.01 in FY 2022)Full year 2023 results: EPS: ₹1.14 (down from ₹14.01 in FY 2022). Revenue: ₹3.00b (down 12% from FY 2022). Net income: ₹64.0m (down 92% from FY 2022). Profit margin: 2.1% (down from 24% in FY 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
分析記事 • Apr 06Quick Heal Technologies' (NSE:QUICKHEAL) Returns On Capital Not Reflecting Well On The BusinessWhat financial metrics can indicate to us that a company is maturing or even in decline? A business that's potentially...
Reported Earnings • Jan 25Third quarter 2023 earnings released: ₹1.70 loss per share (vs ₹2.47 profit in 3Q 2022)Third quarter 2023 results: ₹1.70 loss per share (down from ₹2.47 profit in 3Q 2022). Revenue: ₹702.7m (down 12% from 3Q 2022). Net loss: ₹92.9m (down 165% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year.
お知らせ • Jan 17Quick Heal Technologies Limited to Report Q3, 2023 Results on Jan 24, 2023Quick Heal Technologies Limited announced that they will report Q3, 2023 results on Jan 24, 2023
Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹3.82 (vs ₹5.39 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.82 (down from ₹5.39 in 2Q 2022). Revenue: ₹1.01b (down 2.7% from 2Q 2022). Net income: ₹221.6m (down 36% from 2Q 2022). Profit margin: 22% (down from 33% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Buying Opportunity • Sep 21Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₹242, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 3.3%.
Recent Insider Transactions • Sep 15Insider recently sold ₹4.4m worth of stockOn the 9th of September, Reetu Raina sold around 20k shares on-market at roughly ₹221 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.
Upcoming Dividend • Aug 11Upcoming dividend of ₹4.50 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 26 September 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.6%).
Reported Earnings • Jul 22First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.97 in 1Q 2022)First quarter 2023 results: EPS: ₹0.03 (down from ₹0.97 in 1Q 2022). Revenue: ₹642.8m (up 17% from 1Q 2022). Net income: ₹1.80m (down 97% from 1Q 2022). Profit margin: 0.3% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹200, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 64% over the past three years.
Recent Insider Transactions • Jun 01Head of Research & Development recently sold ₹2.9m worth of stockOn the 25th of May, Bibhuti Kar sold around 16k shares on-market at roughly ₹179 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹14m more than they bought in the last 12 months.
Reported Earnings • May 07Full year 2022 earnings released: EPS: ₹14.01 (vs ₹16.66 in FY 2021)Full year 2022 results: EPS: ₹14.01 (down from ₹16.66 in FY 2021). Revenue: ₹3.61b (up 8.4% from FY 2021). Net income: ₹831.9m (down 22% from FY 2021). Profit margin: 23% (down from 32% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 16Head of Research & Development recently sold ₹1.0m worth of stockOn the 14th of February, Bibhuti Kar sold around 5k shares on-market at roughly ₹203 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.7m. Insiders have been net sellers, collectively disposing of ₹12m more than they bought in the last 12 months.
分析記事 • Jan 26We Like These Underlying Return On Capital Trends At Quick Heal Technologies (NSE:QUICKHEAL)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
Reported Earnings • Jan 25Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹2.47 (up from ₹2.10 in 3Q 2021). Revenue: ₹832.5m (up 19% from 3Q 2021). Net income: ₹142.9m (up 6.1% from 3Q 2021). Profit margin: 17% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.
Recent Insider Transactions • Dec 04Insider recently sold ₹9.7m worth of stockOn the 2nd of December, Nitin Kulkarni sold around 45k shares on-market at roughly ₹217 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹234, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Software industry in India. Total loss to shareholders of 6.2% over the past three years.
分析記事 • Jul 30Most Shareholders Will Probably Agree With Quick Heal Technologies Limited's (NSE:QUICKHEAL) CEO CompensationCEO Kailash Katkar has done a decent job of delivering relatively good performance at Quick Heal Technologies Limited...
Upcoming Dividend • Jul 22Upcoming dividend of ₹4.00 per shareEligible shareholders must have bought the stock before 29 July 2021. Payment date: 05 September 2021. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.8%).
Reported Earnings • Jul 15Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.33b (up 16% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 32% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.
Recent Insider Transactions • Jun 03Insider recently sold ₹1.6m worth of stockOn the 31st of May, Manish Jain sold around 8k shares on-market at roughly ₹216 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹2.9m more than they bought in the last 12 months.
分析記事 • May 31Investors Will Want Quick Heal Technologies' (NSE:QUICKHEAL) Growth In ROCE To PersistWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
Valuation Update With 7 Day Price Move • May 22Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹227, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 18x in the Software industry in India. Total loss to shareholders of 21% over the past three years.
Reported Earnings • May 16Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.57b (up 25% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹181, the stock is trading at a trailing P/E ratio of 14.7x, up from the previous P/E ratio of 12.4x. This compares to an average P/E of 18x in the Software industry in India. Total return to shareholders over the past three years is a loss of 27%.
Is New 90 Day High Low • Mar 05New 90-day high: ₹181The company is up 12% from its price of ₹161 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 27% over the same period.
分析記事 • Feb 17Does Quick Heal Technologies' (NSE:QUICKHEAL) CEO Salary Compare Well With The Performance Of The Company?The CEO of Quick Heal Technologies Limited ( NSE:QUICKHEAL ) is Kailash Katkar, and this article examines the...
Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹2.10 (vs ₹2.77 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹698.8m (up 6.3% from 3Q 2020). Net income: ₹134.6m (down 24% from 3Q 2020). Profit margin: 19% (down from 27% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
分析記事 • Feb 04Are Quick Heal Technologies Limited's (NSE:QUICKHEAL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?Quick Heal Technologies (NSE:QUICKHEAL) has had a rough month with its share price down 8.1%. But if you pay close...
分析記事 • Jan 17Should We Be Excited About The Trends Of Returns At Quick Heal Technologies (NSE:QUICKHEAL)?If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
分析記事 • Dec 28If You Had Bought Quick Heal Technologies' (NSE:QUICKHEAL) Shares Three Years Ago You Would Be Down 49%In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
分析記事 • Dec 10What Type Of Shareholders Make Up Quick Heal Technologies Limited's (NSE:QUICKHEAL) Share Registry?The big shareholder groups in Quick Heal Technologies Limited ( NSE:QUICKHEAL ) have power over the company...
分析記事 • Nov 22Need To Know: Quick Heal Technologies Limited (NSE:QUICKHEAL) Insiders Have Been Selling SharesWe've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Reported Earnings • Nov 07Second quarter 2021 earnings released: EPS ₹4.49The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹902.4m (down 8.5% from 2Q 2020). Net income: ₹288.4m (down 22% from 2Q 2020). Profit margin: 32% (down from 37% in 2Q 2020). The decrease in margin was driven by lower revenue.
